Literature DB >> 23044767

Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis.

Richard Hansen1, Richard K Russell, Caroline Reiff, Petra Louis, Freda McIntosh, Susan H Berry, Indrani Mukhopadhya, W Michael Bisset, Andy R Barclay, Jon Bishop, Diana M Flynn, Paraic McGrogan, Sabarinathan Loganathan, Gamal Mahdi, Harry J Flint, Emad M El-Omar, Georgina L Hold.   

Abstract

OBJECTIVES: The gastrointestinal microbiota is considered important in inflammatory bowel disease (IBD) pathogenesis. Discoveries from established disease cohorts report reduced bacterial diversity, changes in bacterial composition, and a protective role for Faecalibacterium prausnitzii in Crohn's disease (CD). The majority of studies to date are however potentially confounded by the effect of treatment and a reliance on established rather than de-novo disease.
METHODS: Microbial changes at diagnosis were examined by biopsying the colonic mucosa of 37 children: 25 with newly presenting, untreated IBD with active colitis (13 CD and 12 ulcerative colitis (UC)), and 12 pediatric controls with a macroscopically and microscopically normal colon. We utilized a dual-methodology approach with pyrosequencing (threshold >10,000 reads) and confirmatory real-time PCR (RT-PCR).
RESULTS: Threshold pyrosequencing output was obtained on 34 subjects (11 CD, 11 UC, 12 controls). No significant changes were noted at phylum level among the Bacteroidetes, Firmicutes, or Proteobacteria. A significant reduction in bacterial α-diversity was noted in CD vs. controls by three methods (Shannon, Simpson, and phylogenetic diversity) but not in UC vs. controls. An increase in Faecalibacterium was observed in CD compared with controls by pyrosequencing (mean 16.7% vs. 9.1% of reads, P=0.02) and replicated by specific F. prausnitzii RT-PCR (36.0% vs. 19.0% of total bacteria, P=0.02). No disease-specific clustering was evident on principal components analysis.
CONCLUSIONS: Our results offer a comprehensive examination of the IBD mucosal microbiota at diagnosis, unaffected by therapeutic confounders or changes over time. Our results challenge the current model of a protective role for F. prausnitzii in CD, suggesting a more dynamic role for this organism than previously described.

Entities:  

Mesh:

Year:  2012        PMID: 23044767     DOI: 10.1038/ajg.2012.335

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  102 in total

1.  Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease.

Authors:  Mireia Lopez-Siles; Margarita Martinez-Medina; Carles Abellà; David Busquets; Miriam Sabat-Mir; Sylvia H Duncan; Xavier Aldeguer; Harry J Flint; L Jesús Garcia-Gil
Journal:  Appl Environ Microbiol       Date:  2015-08-21       Impact factor: 4.792

Review 2.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

Review 3.  Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics.

Authors:  Mireia Lopez-Siles; Sylvia H Duncan; L Jesús Garcia-Gil; Margarita Martinez-Medina
Journal:  ISME J       Date:  2017-01-03       Impact factor: 10.302

4.  Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals.

Authors:  M Andrea Azcarate-Peril; Andrew J Ritter; Dennis Savaiano; Andrea Monteagudo-Mera; Carlton Anderson; Scott T Magness; Todd R Klaenhammer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

5.  Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease.

Authors:  E Quévrain; M A Maubert; C Michon; H Sokol; P Seksik; F Chain; R Marquant; J Tailhades; S Miquel; L Carlier; L G Bermúdez-Humarán; B Pigneur; O Lequin; P Kharrat; G Thomas; D Rainteau; C Aubry; N Breyner; C Afonso; S Lavielle; J-P Grill; G Chassaing; J M Chatel; G Trugnan; R Xavier; P Langella
Journal:  Gut       Date:  2015-06-04       Impact factor: 23.059

6.  Mucosal microbiome in patients with recurrent aphthous stomatitis.

Authors:  K Hijazi; T Lowe; C Meharg; S H Berry; J Foley; G L Hold
Journal:  J Dent Res       Date:  2014-12-24       Impact factor: 6.116

Review 7.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?

Authors:  Georgina L Hold; Megan Smith; Charlie Grange; Euan Robert Watt; Emad M El-Omar; Indrani Mukhopadhya
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

8.  Metabolic alterations to the mucosal microbiota in inflammatory bowel disease.

Authors:  Michael Davenport; Jordan Poles; Jacqueline M Leung; Martin J Wolff; Wasif M Abidi; Thomas Ullman; Lloyd Mayer; Ilseung Cho; P'ng Loke
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

9.  Paneth cell defects in Crohn's disease patients promote dysbiosis.

Authors:  Ta-Chiang Liu; Bhaskar Gurram; Megan T Baldridge; Richard Head; Vy Lam; Chengwei Luo; Yumei Cao; Pippa Simpson; Michael Hayward; Mary L Holtz; Pavlos Bousounis; Joshua Noe; Diana Lerner; Jose Cabrera; Vincent Biank; Michael Stephens; Curtis Huttenhower; Dermot Pb McGovern; Ramnik J Xavier; Thaddeus S Stappenbeck; Nita H Salzman
Journal:  JCI Insight       Date:  2016-06-02

10.  Functional metagenomic discovery of bacterial effectors in the human microbiome and isolation of commendamide, a GPCR G2A/132 agonist.

Authors:  Louis J Cohen; Hahk-Soo Kang; John Chu; Yun-Han Huang; Emma A Gordon; Boojala Vijay B Reddy; Melinda A Ternei; Jeffrey W Craig; Sean F Brady
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.